Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 56Triple Negative Breast Neoplasms 14Sarcoma 7Neoplasm Metastasis 6Neoplasms 3HER2-negative Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Prostatic Neoplasms 2Inflammatory Breast Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Liposarcoma 1Leiomyosarcoma 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1

Interventions

Ipilimumab 5Radiotherapy 4Nivolumab 4Doxorubicin 4CTLA-4 Antigen 4pembrolizumab 3Gemcitabine 3cabozantinib 2brostallicin 2Sunitinib 2Specimen Handling 2Radiation Dose Hypofractionation 2Radiation 2Magnetic Resonance Spectroscopy 2Ifosfamide 2Docetaxel 2Biopsy 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1talimogene laherparepvec 1spartalizumab 1soblidotin 1sintilimab 1saracatinib 1romidepsin 1reolysin 1perifosine 1pazopanib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Histiocytoma, Malignant Fibrous × eribulin × Clear all
NCT03899805 2025-08-28

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Dana-Farber Cancer Institute

Phase 2 Completed
57 enrolled 14 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡